Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305910 | 0.94 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1LTB4RLTB4R2MEN1 | |
| SCHEMBL10170484 | 0.90 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1KMT2A | |
| SCHEMBL3309179 | 0.90 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1LTB4RLTB4R2MEN1 | |
| SCHEMBL3307241 | 0.87 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1 | |
| SCHEMBL13328128 | 0.86 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1 | |
| SCHEMBL10315902 | 0.85 | MCL1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL10170483 | 0.84 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL10315951 | 0.83 | KDM4E (0.43) | HSP90AA1HSP90AB1 | |
| SCHEMBL3307845 | 0.81 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1 | |
| SCHEMBL13328135 | 0.81 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8816070-B2 | Triazole derivative as an HSP 90 inhibitor | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2102175-B1 | TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR | MERCK PATENT GMBH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-20100113542-A1 | TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR | MERCK PATENT GESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| EP-2102175-A1 | TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR | Merck Patent GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008086857-A1 | TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113542-A1 | TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885LTB4R 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.